Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05894837 | Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases | unknown | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05886465 | HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Jun 2, 2023 |
| NCT03831698 | Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE) | unknown | Phase 2 | 21 | University of Kansas Medical CenterOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT04083365 | Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer(PANDORA) | unknown | Phase 2 | 100 | AUSL Romagna RiminiOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05233332 | Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)(mCRC) | unknown | Phase 2 | 186 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | May 31, 2023 | clinicaltrials |
| NCT05883176 | TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria(B-TACE) | unknown | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05799820 | QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC | unknown | Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 25, 2023 | clinicaltrials |
| NCT03820310 | Clinical Trial of Autologous Tcm Immunotherapy in ICC | unknown | Phase 2 | 20 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT05872841 | H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis | unknown | Phase 2 | 38 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 24, 2023 | clinicaltrials |
| NCT05868317 | Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer | unknown | Phase 2 | 70 | Salah Azaïz Cancer InstituteOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT03553004 | Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial(NIRA-PANC) | unknown | Phase 2 | 18 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05866510 | Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer | unknown | Phase 2 | 47 | Peking UniversityOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05038813 | Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC) | unknown | Phase 2 | 46 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05865132 | Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction | unknown | Phase 2 | 30 | AIPING ZHOUOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05382741 | Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial(VIVA) | unknown | Phase 2 | 182 | Ospedale Policlinico San MartinoOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT05858567 | Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma(RECMULRA-TNT) | unknown | Phase 2 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT05853172 | Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05844371 | Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After Surgery | unknown | Phase 2 | 60 | Yixing People's HospitalOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05845268 | Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer | unknown | Phase 2 | 102 | Beijing Friendship HospitalOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05833672 | Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers | unknown | Phase 2 | 100 | fan liOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05833971 | Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 43 | Guangzhou Institute of Respiratory DiseaseOTHER | 0 | Apr 27, 2023 | clinicaltrials |
| NCT05134532 | Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC(HCC) | unknown | Phase 2 | 40 | CHA UniversityOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT04819971 | Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC | unknown | Phase 2 | 67 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT04609176 | Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | unknown | Phase 2 | 64 | Peking UniversityOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05822453 | Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT04454905 | Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04652440 | Ablation Combined With PD-1 in HCC: Phase II Study | unknown | Phase 1 / Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05818982 | To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC | unknown | Phase 2 | 72 | Peking UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05815290 | Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer | unknown | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05815303 | XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer | unknown | Phase 2 | 92 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05817201 | Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy | unknown | Phase 2 / Phase 3 | 60 | Taizhou HospitalOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05052931 | Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer | unknown | Phase 2 | 10 | Jianjun YangOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05400902 | HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Binkui LiOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05809869 | Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma | unknown | Phase 2 | 25 | The University of Hong KongOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT04389177 | Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001) | unknown | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05799443 | Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer | unknown | Phase 2 | 23 | Fujian Cancer HospitalOTHER_GOV | 0 | Apr 5, 2023 | clinicaltrials |
| NCT05653180 | IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 20 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05791136 | Immunotherapy After Radiotherapy in Elderly ESCC(TREE) | unknown | Phase 2 | 30 | The Central Hospital of Lishui CityOTHER | 0 | Mar 30, 2023 | clinicaltrials |
| NCT04211168 | Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers | unknown | Phase 2 | 44 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04368078 | Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 76 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04443309 | Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC | unknown | Phase 1 / Phase 2 | 53 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05048017 | Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT01628211 | Second Look Laparoscopy in Colorectal Cancer(HIPEC) | unknown | Phase 2 | 140 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01801904 | A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer(PACER) | unknown | Phase 2 | 52 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01898104 | Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer(V-shoRT-R3) | unknown | Phase 1 / Phase 2 | 152 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT02619435 | Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer(STREAM) | unknown | Phase 2 | 46 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05781074 | Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer (CASTLE-08)(CASTLE-08) | unknown | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Mar 24, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2023source: clinicaltrials